QIAGEN Revolutionizes Diagnostic Testing with HSA Approval of QIAstat-Dx Meningitis/Encephalitis Panel

06 February 2024 | Tuesday | News

Groundbreaking Syndromic Testing Solution Enhances Rapid Detection of CNS Infections, Facilitating Timely Patient Care in Singapore

QIAGEN, a global leader in molecular diagnostics, proudly announces the approval of its QIAstat-Dx Meningitis/Encephalitis Panel by the Health Sciences Authority Singapore (HSA). This groundbreaking approval marks a significant advancement in the field of syndromic testing, offering a reliable solution for the rapid detection of central nervous system infections in Singapore.

Meningitis and encephalitis, characterized by inflammation of the protective membranes surrounding the brain and spinal cord, pose serious medical emergencies with potentially fatal consequences. With approximately 2.5 million cases of bacterial meningitis reported annually worldwide, timely diagnosis is paramount for providing effective therapeutic care.

The QIAstat-Dx Meningitis/Encephalitis Panel, leveraging qualitative multiplexed nucleic acid-based technology, empowers healthcare professionals with the capability to simultaneously analyze 15 viral, bacterial, and fungal pathogens within just 80 minutes. This rapid and accurate diagnostic tool facilitates swift clinical decision-making, enabling clinicians to promptly initiate appropriate treatment strategies tailored to individual patients.

"QIAstat-Dx Meningitis/Encephalitis Panel addresses an urgent need for rapid and reliable diagnosis of life-threatening central nervous system infections," stated William Lin, Senior Director, Commercial Operation, APEC at QIAGEN. "Its approval by the Health Sciences Authority Singapore underscores our commitment to providing innovative solutions that enhance patient care and improve health outcomes."

The QIAstat-Dx system, designed for laboratory use, utilizes cost-efficient, single-use cartridges equipped with all necessary reagents and built-in sample processing capabilities. Leveraging multiplex real-time PCR technology, it not only detects and differentiates between multiple pathogens but also provides clinicians with easily interpretable cycle threshold (Ct) values and amplification curves for enhanced diagnostic insights.

This approval further bolsters QIAGEN’s syndromic testing menu in Singapore, complementing existing solutions such as the QIAstat-Dx Respiratory SARS-CoV-2 Panel and QIAstat-Dx Gastrointestinal Panel. With the addition of the Meningitis/Encephalitis Panel, QIAGEN continues to advance diagnostic capabilities, empowering healthcare providers to deliver timely and targeted interventions for improved patient outcomes.

Syndromic testing, powered by multiplexed real-time polymerase chain reaction (PCR), enables simultaneous analysis of multiple pathogens from a single patient sample, facilitating accurate diagnosis and streamlined treatment pathways for patients presenting with overlapping symptoms


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in